12.5.2.30 DHS rekommandationer for KMT 2011.pdf - e-Dok
12.5.2.30 DHS rekommandationer for KMT 2011.pdf - e-Dok
12.5.2.30 DHS rekommandationer for KMT 2011.pdf - e-Dok
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
following high-dose sequential chemotherapy and in vivo rituximab-purged stem cell autografting (R-HDS<br />
regimen). Blood. 2003 Jul 15;102(2):749-55.<br />
Geisler CG, Kolstad A, Laurell A, et al. Long-term progression-free survival of mantle cell lymphoma after<br />
intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2<br />
multicenter study by the Nordic Lymphoma Group. Blood 112:2687-2693, 2008<br />
Hicks L, Connors JM, Mangel J, Buckstein R et al. Autologous Stem-Cell Transplant with a Rituximab Purge and<br />
Maintenance vs. Standard Chemotherapy <strong>for</strong> Mantle Cell Lymphoma: Extended Follow-Up of a Matched Pair<br />
Analysis. Blood 108, 2006 (Abstract 3051)<br />
Lefrere F, Delmer A, Suzan F et al. Sequential chemotherapy by CHOP and DHAP regimens followed by highdose<br />
therapy with stem cell transplantation induces a high rate of complete response and improves event-free<br />
survival in mantle cell lymphoma: a prospective study. Leukemia 16:587-593, 2002<br />
AlloHCT<br />
GVL:<br />
Khouri IF, Lee MS, Romaguera J, Mirza N, Kantarjian H, Korbling M, Albitar M, Giralt S, Samuels B, Anderlini P,<br />
Rodriguez J, von Wolff B, Gajewski J, Cabanillas F, Champlin R. Allogeneic hematopoietic transplantation <strong>for</strong><br />
mantle-cell lymphoma: molecular remissions and evidence of graft-versus-malignancy.<br />
Ann Oncol. 1999;10:1293-9<br />
Maris MB, Sandmaier BM, Storer BE, Chauncey T, Stuart MJ, Maziarz RT, Agura E, Langston AA, Pulsipher M,<br />
Storb R, Maloney DG. Allogeneic hematopoietic cell transplantation after fludarabine and 2 Gy total<br />
body irradiation <strong>for</strong> relapsed and refractory mantle cell lymphoma. Blood. 2004 Dec 1;104(12):3535-42.<br />
Sorror ML, Storer B, Sandmaier BM, Maris M, et al. Sustained Graft versus lymphoma effect among patients<br />
with mantle cell lymphoma given non-myeloablative hematopoietic cell transplantation. 2008, ASH abstract 2147<br />
Tam CS, Bassett R, Ledesma C, Korbling, (..Khouri I) et al. Mature results of the M. D. Anderson cancer center<br />
risk adapted transplantation strategy in mantle cell lymphoma. Blood. 2009, 113: 4144-52.<br />
Myeloablativ alloHCT:<br />
Armitage JO. Allotransplants <strong>for</strong> mantle cell lymphoma: Ann Oncol 2002;13:9a<br />
Khouri IF, Lee MS, Romaguera J, Mirza N, Kantarjian H, Korbling M, Albitar M, Giralt S, Samuels B, Anderlini P,<br />
Rodriguez J, von Wolff B, Gajewski J, Cabanillas F, Champlin R. Allogeneic hematopoietic transplantation <strong>for</strong><br />
73
Change language